TownSquare Capital’s Adaptimmune Therapeutics ADAP Stock Holding History

TownSquare Capital’s Portfolio ADAP Stock Details ADAP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-29,739	Closed	-$247K	–	494
2020 Q3	$247K	Buy	+29,739	New	+$260K	0.01%	371

Other funds holding ADAP

MCMC

Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

TownSquare Capital's ADAP Position: Q4 2020 in Review

TownSquare Capital sold out of Adaptimmune Therapeutics (ADAP) in Q4 2020, closing a stake of 29,739 shares — an estimated $247K sold.

TownSquare Capital first reported a position in ADAP in Q3 2020 and held it in 1 quarter. The position peaked at $247K in Q3 2020. 87 funds tracked by Wall St. Rank hold ADAP as of Q4 2020.

TownSquare Capital reported no remaining Adaptimmune Therapeutics position as of Q4 2020 after selling out during the quarter.
TownSquare Capital sold 29,739 Adaptimmune Therapeutics shares in Q4 2020, an estimated $247K.
TownSquare Capital first reported a position in Adaptimmune Therapeutics in Q3 2020 and held it in 1 quarter.
TownSquare Capital's Adaptimmune Therapeutics position peaked at $247K in Q3 2020.
87 funds tracked by Wall St. Rank held Adaptimmune Therapeutics as of Q4 2020.

Based on TownSquare Capital's 13F filing for Q4 2020, filed 16 Feb 2021.